17 June 2022
This article I want to share with the SI MHMS and the oncologists doctors at the NRH is important in the context of screening and catching breast cancer in its early stages before it is discovered in the body too late and spread into other parts of the body and possibly into vital lymph glands.
I again appeal for a breast screening programme to be introduced as a matter of priority at the NRH Cancer Unit.
The Blessing Cancer Center in the USA has been selected as one of 51 study locations worldwide participating in a new metastatic breast cancer clinical trial.
Metastatic cancer has travelled to other parts of the body from its site of origination. It is estimated that 20-30 per cent of all breast cancer cases will become metastatic. The clinical trial is studying the effectiveness, safety and tolerability of a first-of-its-kind medication, Enobosarm.
“Enobosarm works differently in the body than any other medication approved for metastatic breast cancer currently available,” said Kiley McGlauchlen, MS, CCRP, Director, Clinical Research, Blessing Health System.
Enobosarm can also help patients in two ways
“The medication helps fight cancer and also treats how the cancer is affecting the patient’s quality of life and physical function,” McGlauchlen continued. “Cancer-induced muscle wasting can lead to pain, weakness and other related complications. Enobosarm may have a dual benefit, improving outcomes through its anticancer properties and its potential for preventing muscle wasting.”
“The medication shows great promise for treating metastatic breast cancer, an area where there is great need, with this additional benefit of improving physical function that would be very helpful to this patient group,” she concluded. “We are excited to be a study location for this worldwide clinical trial.”
Kellie Flippin, MD, fellowship trained and board-certified medical oncologist, Blessing Cancer Center, is the principal investigator for the local trial.
“We’re very excited by the study,” said Dr. Flippin. “It provides a novel mechanism of anti-breast cancer treatment not otherwise available in the community. We think it will prove to be a better option than the current gold standard of chemotherapy.”
Women with ER positive/HER2 negative metastatic breast cancer that has not responded to standard treatment can go to blessinghealth.org/studies and use the Contact Us link, or call 217-223-8400, ext. 7201, to learn more about the possibility of becoming involved in the clinical trial.
Blessing is involved with two other clinical trials currently and plans to begin participating in two more soon.
Source -This article originally appeared on The McDonough County Voice: Blessing participates in new cancer treatment trial
Yours sincerely
Frank Short
